Medicaid misclassification bill inspired by EpiPen snafu passes Congress

Mylan famously classified EpiPen as a generic on Medicaid when it should have been in the innovative drug class—a move that cut Mylan's rebate tally by hundreds of millions of dollars. Now, lawmakers have passed a bill cracking down on those misclassifications.